GSK (GSK)

Sector:

Pharma and Biotech

Index:

FTSE 100

1,448.00p
   
  • Change Today:
      22.50p
  • 52 Week High: 1,774.50
  • 52 Week Low: 1,264.00
  • Currency: UK Pounds
  • Shares Issued: 4,100.23m
  • Volume: 7,237,685
  • Market Cap: £59,371m
  • RiskGrade: 129
  • Beta: 0.00

Latest ShareCast News

GSK's COPD treatment approved by FDA

By Benjamin Chiou

Date: Friday 23 May 2025

(Sharecast News) - Pharma group GSK has announced that US regulators have approved for use its Nucala treatment for adults with chronic obstructive pulmonary disease (COPD) following positive results from phase III trials.

GSK ShareCast News

GSK's blood cancer treatment approved in Japan 19-May-2025 ShareCast
London close: Stocks finish choppy week in the b... 16-May-2025 ShareCast
GSK buys Boston's developmental liver disease dr... 14-May-2025 ShareCast
Pharma stocks slide as Trump threatens price cut... 12-May-2025 ShareCast
Sunday newspaper round-up: US-China, Aerospace, ... 11-May-2025 ShareCast

GSK Regulatory News

Transaction in Own Shares 27-May-2025 07:00 RNS
positive CHMP opinion on Blenrep in EU 23-May-2025 12:16 RNS
Transaction in Own Shares 23-May-2025 07:00 RNS
FDA approves Nucala COPD indication 23-May-2025 07:00 RNS
Transaction in Own Shares 22-May-2025 07:00 RNS

GSK Newspaper Links

GlaxoSmithKline scraps sale of old drugs 05-Dec-2014 Telegraph
Glaxo sharpens axe to save £1bn as insurers and ... 01-Dec-2014 The Independent
GSK to cut hundreds of US jobs 01-Dec-2014 Telegraph
Ebola vaccine trials 'encouraging', says GSK 27-Nov-2014 Telegraph
GlaxoSmithKline tops table in effort to get drug... 17-Nov-2014 Guardian

GSK Tips & Analysis

Questor :GlaxoSmithKline 16-Apr-2014 Telegraph
Questor:GlaxoSmithKline 06-Oct-2011 Telegraph
Questor:GlaxoSmithKline 11-Aug-2011 Telegraph
Questor tip: GlaxoSmithKline 28-Jul-2011 Telegraph
Investment Column: GlaxoSmithKline 27-Jul-2011 The Independent

GSK News Wires

FDA Approves Promacta(R) (Eltrombopag), the Firs... 20-Nov-2008 PR Newswire
Study Found That Long Term Use of Advair Diskus(... 29-Oct-2008 PR Newswire
GlaxoSmithKline to Acquire Genelabs Technologies... 29-Oct-2008 PR Newswire
A New Interactive Consumer Experience Highlighti... 28-Sep-2007 PR Newswire
AUDIO from Medialink and GlaxoSmithKline: A New ... 28-Sep-2007 PR Newswire

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

GSK Market Data

Currency UK Pounds
Share Price 1,448.00p
Change Today 22.50p
% Change 1.58 %
52 Week High 1,774.50
52 Week Low 1,264.00
Volume 7,237,685
Shares Issued 4,100.23m
Market Cap £59,371m
Beta 0.00
RiskGrade 129

GSK Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
44.05% below the market average44.05% below the market average44.05% below the market average44.05% below the market average44.05% below the market average
23.40% above the sector average23.40% above the sector average23.40% above the sector average23.40% above the sector average23.40% above the sector average
Price Trend
13.86% above the market average13.86% above the market average13.86% above the market average13.86% above the market average13.86% above the market average
53.19% above the sector average53.19% above the sector average53.19% above the sector average53.19% above the sector average53.19% above the sector average
Income
74.90% above the market average74.90% above the market average74.90% above the market average74.90% above the market average74.90% above the market average
100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average
Growth
37.24% below the market average37.24% below the market average37.24% below the market average37.24% below the market average37.24% below the market average
48.39% below the sector average48.39% below the sector average48.39% below the sector average48.39% below the sector average48.39% below the sector average

What The Brokers Say

Strong Buy 4
Buy 2
Neutral 14
Sell 3
Strong Sell 1
Total 24
neutral
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

GSK Dividends

  Latest Previous
  Q1 Q4
Ex-Div 15-May-25 20-Feb-25
Paid 10-Jul-25 10-Apr-25
Amount 16.00p 16.00p

Trades for 27-May-2025

Time Volume / Share Price
16:05 0 @ 1,451.00p
16:01 1 @ 1,452.00p
15:52 1 @ 1,454.00p
15:13 5 @ 1,452.50p
14:56 10 @ 1,453.00p

GSK Key Personnel

CEO Emma Walmsley

Top of Page